Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New portable device could bring glaucoma screening to remote areas

NCT ID NCT07674069

Diagnosis Sponsor: Buckinghamshire Healthcare NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This pilot study tests a new, portable device called the World Sight Foundation Field Machine (WSFFM) for measuring visual field loss in glaucoma patients. The WSFFM is compared to the standard Humphrey Visual Field analyzer to see if it can accurately detect glaucoma damage. If successful, the WSFFM could help doctors in lower-income countries diagnose glaucoma earlier and prevent vision loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
World Sight Foundation Field Machine (WSFFM) device
What this could lead to
If the WSFFM proves accurate and easy to use, it could enable earlier glaucoma diagnosis and treatment in lower-income countries, helping prevent irreversible vision loss.
What could go wrong
This is a small pilot study (100 participants) comparing a new device to the gold standard. The WSFFM may not match the Humphrey analyzer's accuracy, and results may not generalize to real-world settings in low-resource areas.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Patients attending glaucoma outpatient clinic * Patients requiring visual field testing, with plan for "SITA-STANDARD" HVF testing * Patients 18 years or older and of any gender * Patients capable of giving informed consent. Exclusion Criteria: * \- Patients not requiring visual field testing on that outpatient clinic attendance. * Patients requiring visual field testing, with plan for "SITA-FAST" or "SITA-FASTER" HVF testing. * Patients who do not attend their outpatient clinic appointment, * Patients not able to perform visual field testing (for example due to their visual acuity, physical difficulty in positioning for test duration, or cognitive difficulties in understanding instructions). * Patients under the age of 18 years old.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Buckinghamshire Healthcare NHS Trust

    RECRUITING

    Aylesbury, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.